Clinical trial
An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability…
NCT01658878 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT01658878 |
|---|---|
| Title | An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer |
| Official title | A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular… |
| Acronym | CheckMate040 |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | Ono Pharmaceutical Co. Ltd Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hepatocellular Carcinoma |
| Intervention type | Biological, Drug |
| Interventions | Nivolumab, Sorafenib, Ipilimumab, Cabozantinib |
| Enrollment | 657 |
| Start date | Oct 30, 2012 |
| Primary completion | Nov 12, 2024 |
| Completion | Nov 12, 2024 |
| First posted | Aug 7, 2012 |
| Last update posted | Dec 24, 2025 |
| Countries | Canada, France, Germany, Hong Kong, Italy, Japan, Puerto Rico, Singapore, South Korea, Spain, Taiwan, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: